1. Home
  2. Analysis
  3. Ramipril
  4. Ultiva

Ramipril and Ultiva drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Ramipril and Ultiva. Common interactions include drug ineffective among females and anaphylactic shock among males.

The phase IV clinical study analyzes what interactions people who take Ramipril and Ultiva have. It is created by eHealthMe based on reports of 6 people who take Ramipril and Ultiva from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Sep, 18, 2023

6 people who take Ramipril and Ultiva together, and have interactions are studied.

What is Ramipril?

Ramipril has active ingredients of ramipril. It is often used in high blood pressure. eHealthMe is studying from 139,090 Ramipril users for its effectiveness, alternative drugs and more.

What is Ultiva?

Ultiva has active ingredients of remifentanil hydrochloride. eHealthMe is studying from 1,641 Ultiva users for its effectiveness, alternative drugs and more.

Number of Ramipril and Ultiva reports submitted per year:

Ramipril and Ultiva drug interactions.

Common Ramipril and Ultiva drug interactions by gender *:

female:

  1. Drug ineffective
  2. Acute pulmonary oedema
  3. Anaphylactic shock

male:

  1. Anaphylactic shock
  2. Aortic valve incompetence
  3. Glomerulonephritis
  4. Lung disorder
  5. Mitral valve incompetence
  6. Nosocomial infection
  7. Post procedural haemorrhage
  8. Renal failure acute

Common Ramipril and Ultiva drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Drug ineffective

50-59:

n/a

60+:

  1. Anaphylactic shock
  2. Acute pulmonary oedema
  3. Aortic valve incompetence
  4. Glomerulonephritis
  5. Lung disorder
  6. Mitral valve incompetence
  7. Nosocomial infection
  8. Post procedural haemorrhage
  9. Renal failure acute

* Approximation only. Some reports may have incomplete information.

Do you take Ramipril and Ultiva?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Ramipril and Ultiva:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Ramipril side effects:

Browse all side effects of Ramipril:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Ultiva side effects:

Browse all side effects of Ultiva:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Ramipril interactions:

Browse all interactions between Ramipril and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Ultiva interactions:

Browse all interactions between Ultiva and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on ramipril and remifentanil hydrochloride (the active ingredients of Ramipril and Ultiva, respectively), and Ramipril and Ultiva (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Ramipril and Ultiva.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2023 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.